News | May 08, 2024
AstraZeneca completes equity investment agreement with Cellectis
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Aptar Closures’ E-Disc Top securely protects against in-transit leakage while eliminating the need for liners and extra shipping preparation fees
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
Subscribe To Our Newsletter & Stay Updated
